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                                                        ABSTRACT 
BACKGROUND : 
             Diabetes  mellitus  is  a  group  of  metabolic  disorders  characterised  
by  chronic  hyperglycaemia  associated  with  disturbance  of  carbohydrate, fat  
and  protein  metabolism  due  to  absolute  or  relative  deficiency  in  insulin  
secretion  or  its  action. Treatment  should  be  based  on  underlying  
pathophysiology  not  on  symptoms. 
 
AIM  OF  THE  STUDY : 
1. In  type 2  DM  patients,  estimation  of  C-peptide  levels  to assess the   
level  of  insulin secretion  in  the  body. 
2.  Obesity  and  C-peptide  level  correlation  in  patients  with  type 2  DM.  
3. Treatment  modification  in  type  2  DM  patients  based  on  C- peptide  
levels. 
 
 
Settings & designs : 
It  is  a  prospective  study  done  in  the  diabetic  outpatient   clinic  of   our      
hospital. 
 
  
Materials & methods : 
From  Dec  2014  to  May 2015,  50  type 2 diabetic patients were  evaluated  
for  fasting  plasma  glucose  level,  fasting  C-peptide  level  and  BMI  
taking  into  account  the  inclusion  and  exclusion  criterias. 
 
INCLUSION  CRITERIA  : 
       Patients  labelled  as  type 2  diabetes  mellitus. 
 
EXCLUSION  CRITERIA : 
a. Type 1  diabetes mellitus  patients. 
b. Patients  with  acute  infections, renal failure  and  pregnancy. 
 
  
       KEY  WORDS  :  
         Type  2  DM ,  C- peptide,  BMI,  duration  of  diabetes  mellitus,  insulin   
resistance,  blood  sugar,  β  cell  of  pancreas,  family  history  of  diabetes.  
Glycosylated  haemoglobin. 
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    INTRODUCTION 
 
 
 
 
   
 
                                    
  
INTRODUCTION  : 
Diabetes mellitus is the commonest  endocrine  disorder  in  population. This  
clinical  syndrome  due  to  either  absolute  or  relative  insulin  deficiency. 
Currently  number  of  diabetics  worldwide  is  160 million
1
.  In  India  the  
projected  increase  is  from  20  to  62  million
2,3 
. 
 The  term  diabetes  is  derived  from  Greek  words  „Dia‟  meaning  „through‟,  
„Bainein‟  meaning  „to go‟. This  disease  causes  loss  of  weight  as  if  the  
body  mass   is  passed  through  urine. It  is  a  disease  known  from  ancient  
times.  Charaka  in  his  treatise,  elaborated  this  disorder  as  „Madhumeha‟  
(meaning  sweet  urine)  around  400 BC
4
. Type 1 DM  is  caused  by  
pancreatic  β cell  destruction  by  auto antibodies,  leading  to  defect  in  
insulin  synthesis  and  secretion
5
.  Type 2  DM  results  from  a  combination  
of  impaired  β  cell  function6  and  marked  increase  in  peripheral  insulin  
resistance  at  receptor/ post receptor  levels.  Their  circulatory  levels  of  
insulin  may  be  variable  from  hyper  to  normo insulinemic   levels  in  
majority  of  patients.  Type  2  DM  is  a  major  health  problem  worldwide
7
.  
Its  development  can  be  prevented  in  many  instances
8
.  A  family  history  of  
diabetes , an  increase  in  BMI  and  impaired  insulin  secretion  and  action  
are  important  risk  factors
9
.   Studies  from  Urban  India  suggests  that  one  in  
four  adults  over  the   age  of  20 years  has  IGT  or  DM
10
.                      ( 1 )                                                                    
  
Type 2 DM  causes  long  term  damage ,  dysfunction  and  failure  of  various  
organs  especially  the  eyes,  kidneys,  nerves,  heart  and  blood  vessels.  
Complications  include  both  micro  &  macro  angiopathy.  Though  macro 
angiopathy  is  the  major  cause  of   morbidity  and  mortality,  the  
microvascular  complications  are  more  common. The  incidence  of   type 2  
DM  is  on  the  rise. 
The  mortality  from  cardiovascular  disease  and  the  incidence  of  non- fatal  
coronary  heart  disease  is  2-4  times  higher  in  patients  with  NIDDM   than  
in  normal  subjects  and  is  the  major  cause  of  death  in  these  patients
11
.   
It  is  a  proven  fact  that  diabetes  mellitus  is  an  ongoing ,  chronic  
progressive  disorder. Its  progressive  nature  is  not  only  in  terms  of   
worsening  hyperglycaemia  but  also  a  relentlessly  progressive  nature  of  its  
various  complications.  Treatment  should  be  based  on  underlying  
pathophysiology  of  diabetes  mellitus  not  on  symptoms,  taking  into  
account  the  insulin  secretory  capacity  of  pancreatic  β cell  and   peripheral  
resistance  to  insulin  action  occurring  primarily  in  liver,  muscle   and  
adipose  tissue. 
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                                     REVIEW  OF  LITERATURE 
HISTORY : 
INSULIN : 
              Insulin  is  one  of  the  hormones  known  from  ancient  times. In  
1869,  Langerhans  identified  alpha  and  beta  cells  in  islets  of  pancreas.  In  
1909,  De Meyer  named  the  hypothetical  secretion  from  pancreas  as  
Insulin  from  the  word  „Insula‟  meaning  island  (i.e)  Islet  of  Langerhans. 
              In  1922,  Banting  and  Best  extracted  the  insulin  from  pancreas. It  
was  the  first  hormone  to  be  isolated  in  pure  form.  Previous  workers  
failed  to  isolate, as  trypsin  digested  insulin  beforehand.  Banting  and  Best  
circumvented  this  problem  by  ligating  the  pancreatic  duct  and  waiting  for  
7  weeks.  This  caused  acinar  cells  producing  trypsin  to  atrophy.  For  this  
Banting  was  awarded  Nobel prize  in  1923.  In  1954  Sanger  studied  the   
aminoacid  sequence  of  insulin;  first  protein  with  complete  aminoacid  
sequencing  done.  He  was  awarded  Nobel  prize  in  1958.  Insulin  was  the  
first  protein  to  be  synthesized  in  1964. 
C- PEPTIDE : 
         In  1967,  Donsteiner  and  his  co- workers
12
  discovered  the  pro – 
insulin. In  1969,  Rubenstein  et  al
13
  detected  C- peptide  in  human  serum.  
Between  1973  and  1976,  there  is  a  considerable  increase  of                  (4) 
  
immunological  studies.  Chemically  synthesized  C-peptides,  their  derivatives  
and  fragments  allow  exploring  the  immunological  properties  of  human  C-
peptide
14
.  The  enzyme  responsible  for  conversion  of  pro – insulin  to  
insulin  and  C- peptide  was  discovered  in  1990/1991
15
. 
HAEMOGLOBIN  A1C  : 
        HbA1c  was  first  separated  from  other  forms  of  haemoglobin  by  
Huisman  and  Meyering  in  1958  using  a  chromatographic  column 
16
.  It  
was  characterised  as  a  glycoprotein  by  Bookchin  and  Gallop  in  1968.  Its  
increase  in  diabetes  was  first  described  in  1969  by  Samuel  Rahbar  and  
his  co-workers
17
.  The  use  of  HbA1c  for  monitoring  the  degree  of  glucose  
control  in  diabetic  patients  was  proposed  in  1976  by  Anthony  Cerami,  
Ronald  Koenig  and  co-workers. 
 
INSULIN : 
Insulin  has  varied  effects  on  every  organ  system  in  the  body.  Hence  a  
brief  overview  of  the  structure  and  physiologic  effect  of  insulin  is  
needed,  to  understand  the  manifestations  of  diabetes. 
 
                                                                                                                        (5) 
  
     FORMATION  AND  SECRETION  OF  INSULIN  : 
 
      1. STRUCTURE  OF  INSULIN : 
Insulin  is  a  protein  hormone  with  2  poly peptide  chains;  the  A  chain  
with  21  amino acids  and  B  chain  with  30  amino acids  linked  together  
by  disulfide  bridges.  There  is  another  intra chain  disulfide  bridges  
between  6
th
  and  11
th
  residues.  There  are  minor  differences  in  the  
amino acid  composition  from  species  to  species.  If  insulin  of   one  
species  is  injected  into  another,  it  induces  antibody  formation. 
 
2. ANATOMY  OF  THE  ISLET  CELLS : 
The  Islets  of  Langerhans  are  ovoid  collections  of  cells  scattered  
throughout  the  pancreas,  more  in  tail  than  head  or  body.  They  
constitute  around  2%  of  volume  of  the  gland.  There  are  around  1-2  
million  islets.  Each  islet  is  0.3mm  in  diameter  surrounded  by  
fenestrated  capillaries.  It  contains  4  different  types  of  cell  types  
namely  A,  B,  D  and  F. „A‟  cells  secrete  glucagon;  „B‟  cells  secrete  
insulin;  „D‟ cells  secrete  somatostatin  and   „F‟ cells  secrete  polypeptide.  
B  cells  constitute  60%  of  the  islet  cells  located  in  the  centre  of  each  
islet.  The  B  cell  granules  are  packets  of  insulin  with  zinc  
aggregates
18
.                                                                                                (6) 
  
 
1.  SYNTHESIS  OF  INSULIN : 
Insulin  like  other  polypeptide  hormone  is  synthesized  as  prepro insulin  
containing  108  amino acids  with  molecular  weight  of  11500 MW .  The  
gene  for  insulin  is  located  in  the  short  arm of  chromosome  11;  has  
two  introns  and  three  exons.  This  has  23 – amino acid  signal  peptide 
(leader  sequence)  which  is  hydrophobic  and  is  cleaved  as  it  passes  
through  cisternae  of  endoplasmic  reticulum.  Pro insulin  so  formed  
provides  configuration  necessary  for  disulphide  bridges.    The  pro 
insulin  contains  84  amino acids  and  is  transported  to  golgi  apparatus.  
The  amino terminal  of  pro insulin  is  the  B chain;  then  a  connecting  
sequence  called  C-peptide .  Pro insulin  is  cleaved  to  insulin  &  C-
peptide  by  enzymes  trypsin  and  carboxy peptidase – B. The  site  specific  
cleavages  occur  between  arginine  residues  at  position  31  and  32,  as  
well  as  lysine  and  arginine  at  position  64  and  65  of  the  pro insulin.  
Equimolar  concentrations  of  C-peptide  with  33  amino acids  and  insulin  
with  51  amino acids  are  thus  formed.  Then  they  are  packaged  into  
secretory  granules  in  the  golgi apparatus.  These  granules  mature  as  
they  traverse  the  cytoplasm  towards  the  plasma  membrane.  About  95 
%  of  pro insulin  is  converted  into  insulin  within  the  secretory  granules. 
Both  pro insulin  and  insulin  combine  with  zinc  in  the  granules  to  form  
hexamers.                                                                                                      (7) 
  
 
 
.
 
 
 
 
 
4)   INSULIN  SECRETION  :   Insulin  is  released  from  β  cells  by  the  
process  of  emiocytosis.  Microtubules  along  with   microfilaments ( actin  & 
                                                                                                                    (8)  
  
myosin )  play  an  important  role  in  insulin  secretion. Glucose,  the  most  
important  physiological  substance  involved  in  regulation  of  insulin  release.  
Insulin  secretion  is  greater  after  oral  than  after  intravenous  glucose  by  
incretin  effect.   
Approximately  50 %  of  the  total  insulin  secreted  into  the  portal  system  is  
removed  during  initial  passage  through  liver ( first pass effect) ,  which  
leads  to  2.5 – 3  times  greater  concentration  of  insulin  in  the  portal  vein  
compared  with  a   peripheral  vein
19
.  More over  the  fractional  hepatic  
extraction  of  insulin  is  variable.   
Insulin  clearance  also  occurs  in  the    kidney,  with  normal  kidney  
removing nearly  40 %  of  insulin  presented  to  it
20
.  The  pro insulin  related  
peptides  constitute  20 %  of  total  circulating  insulin  like  immune  reactivity.  
It  has  been  estimated  that  the  biologic  potency  of  pro insulin  is  only  10 
%  of  insulin,  under  normal  physiologic  conditions.  The  in vivo  effects  of  
pro insulin  are  negligible.  
 
KINETICS  OF  INSULIN  SECRETION : 
      Glucose  is  the  major  physiological  determinant  of  insulin  secretion.  
Insulin  release  is  stimulated  by  transport  of  glucose  into  β  cells  of  the  
pancreas  via  glucose  transporter ( GLUT 2).  Glucose                             (9) 
  
stimulated  insulin  release  is  biphasic : Initial  response  is  a  transient  rapid  
rise  in  release  which  terminates  in  5-10  minutes  - first  phase ( acute  
insulin  response ). This  first  phase  response  is  important   in  maintaining  
normal  glucose  tolerance,  suppresses  glucose  production  in  the  body  and  
prevents  postprandial  hyperglycemia.  The  second  phase  is  the  prolonged  
phase,  which  persists  during  stimulus  of  the  high  glucose
21
. 
STIMULATORS  OF  INSULIN  RELEASE : 
1. Nutrients  : 
a. Glucose 
b. Amino acids  -  Arginine  is  a  powerful  stimulant.  Leucine  is  also  
a  potent  stimulator
22
. 
c. Fat  regulation :  Small  increase  in  insulin  secretion  occurs  
following  ingestion  of  medium  chain  fats. 
 
2. Hormonal  :  Gut  hormones  like  Gastric  inhibitory  polypeptide  &  
GLP-1  may  mediate  the  incretin  effect  by  stimulating  greater insulin  
release  following  oral  ingestion  rather  than  parenteral  administration  
of  glucose. 
 
 
                                                                                                           (10) 
  
Neural  :   Hypothalamo - entero – insular  axis   via  vagus  nerve  stimulates  
insulin  release  on  sight,  smell  of  food.  Minimizes  early  rise  of  
postprandial  plasma  glucose.     
 
 
CELLULAR  ACTIONS  OF  INSULIN  : 
Insulin  mediates  its  intracellular  effect  by  binding  to  its  receptor  which  is  
present  on  the  external  surface  of  cell.  The  receptor  is  a  glycoprotein  
with    2α   and  2β   subunits. 
After  binding  to  the  receptor  site  present  in  α  subunit,  insulin  activates  
the  β  subunit‟s  protein  kinase  activity  leading  to  phosphorylation  of  
several  tyrosine  residues
24
,  which  mediates  multiple  intracellular  events.  
As  an  example,  activation  of  PI-3  kinase  pathway  stimulates  translocation  
of  glucose  transporters (GLUT 4)  to  the  cell  surface.   
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              DIAGRAM  DEPICTING  EFFECTS  OF  INSULIN  ACTION 
 
 
 
 
 
                                                                                                               (13)                                                                                                                                          
  
                     PHYSIOLOGICAL  ACTIONS  OF  INSULIN  
 
EFFECT  ON  CARBOHYDRATE  METABOLISM : 
The  entry  of  glucose  into  muscle  and  adipose  tissue  via   Glucose  
Transporters  ( GLUT 4)  is  mediated  by  insulin   except  in  nervous  tissue.  
It  increases  rate  of  entry  of  glucose  into  the  muscle  15  fold.  In  the  liver  
insulin  induces  glucose  uptake.  Infact  most  of  the  glucose  absorbed  from  
GIT  is  taken  up  by  liver  and  converted  to  glycogen.  In  between  meals,  
this  glycogen  is  converted  back  to  glucose  and  released  into  the  
circulation.  Thus  glucose  level  is  maintained  within  a  constant  range. 
Glucose  uptake  and  storage  in  the  liver  occurs  with  the  help  of  insulin  
by   multiple  mechanisms : 
1. An  enzyme  phosphorylase  pertaining  to  the  liver  is  inactivated -  this  
prevents  glycogenolysis. 
2. Increases  glucokinase  activity,  which  phosphorylates  glucose  and  
hence  the  phosphorylated  glucose  cannot  diffuse  out  of  the  liver. 
3. Insulin  increases  activity  of  the  enzyme  glycogen  synthetase  and  
hence  glycogen  synthesis. 
 
                                                                                                                          (14) 
  
EFFECT  ON  FAT  METABOLISM : 
Insulin  has  several  effects  that  lead  to  fat  storage  in  adipose  tissue.  
Insulin  increases  glucose  utilisation  by  most  of  the  body‟s  tissues,  which  
automatically  decreases  fat  utilisation.  So  insulin  acts  as  a  fat  sparer  and  
promotes  fatty acid  synthesis.  This  happens  when  more  carbohydrates  are  
consumed  than  which  is  needed  for  energy,  thus  providing  substrate  for  
fat  synthesis.  This  is  achieved  by  conversion  to  pyruvate,  which  is  then  
converted  to  acetyl  COA  the  substrate  from  which  fat  can  be  synthesised.  
The  triglycerides  thus  formed  are  incorporated  into  lipoproteins  mainly  
VLDL  and  transported  to  the  blood  from  where  they  are  taken  up  by  
other  cells,  especially  the  adipose  tissue. 
 
Insulin  activates  lipoprotein  lipase,  which  increases  triglyceride  uptake  into  
fat  cells.  Insulin  has  two  more  effects  pertaining  to  fat  metabolism  : 
1. It  inhibits  hormone  sensitive  lipase. 
2. Insulin  promotes  glucose  transport  through  the  cell  membrane  into  
fat  cells.  This  forms  L – glycerol  phosphate  which  supplies  the  
glycerol  that  combines  with  fatty acids  to  form  triglycerides. 
 
                                                                                                                          (15) 
  
EFFECTS  ON  PROTEIN  METABOLISM : 
Insulin  causes  active  transport  of  many  aminoacids  into  the  cells. Thus, it  
plays  an  important  role  in  protein  anabolism  and  positive  nitrogen  
balance,  by  favouring  protein  synthesis  and  preventing  its  degradation. 
 
                             SIGNIFICANCE   OF  C- PEPTIDE 
 
C- peptide  is  used  as  a  measure  of  insulin  secretion  in  humans.  Because  
serum  insulin  level  is  affected  by  various  factors  like  exogenous  insulin  
administration  and  significant  amount  of  secreted  insulin  undergoes  
hepatic  extraction  before  it  appears  in  the  peripheral  blood
32
,  while  
secreted  C- peptide  undergoes  only  minimal  change  and  its  level  in  the  
peripheral  blood  equals  to  that  of  in  the  portal  blood. 
 
CHEMISTRY  AND  SYNTHESIS   : 
Human  insulin  and  C- peptide  are  synthesised  as  a  single  polypeptide  
chain  known  as  proinsulin  in  the  pancreatic  islet  by  the                       
 
                                                                                                                       (16) 
  
beta  cells.  Proinsulin  is  cleaved  proteolytically  to  form  equimolar  amounts  
of  mature  insulin  and  C- peptide  which  are  released  into  the portal  vein. 
            It  is  called  as  C- peptide  because  it  connects  the  A  and  B  chains  
of insulin.  C – peptide  is  a  single  peptide  chain  of  31  aminoacids  with  
molecular  weight  of  30,200.  Half  life  of  C- peptide  is  about  30  minutes. 
 
 
 
                                                                                                                                                                            (17) 
  
                       
             Figure 5 -   PHYSIOLOGICAL  EFFECTS  OF  C – PEPTIDE  : 
 
 
C – peptide  has  previously  been  considered  to  be   without  intrinsic  
physiological  effects.  However  recent  studies  have  suggested  that  C – 
peptide  in  physiological  concentrations  increases  glucose  transport  and  
glycogen  content  in  skeletal  muscle
33
.                                                         (18) 
  
In  IDDM  patients,  short  term  2 hour  infusion  of  C – peptide  to  a  steady  
state  plasma  level  of  0.8  nmol/l (2.45 ng/ml ) , significantly  increases  the  
whole  body  glucose  uptake  by  about  25 %.  A  further  uptake  of  15 %  of  
glucose  was  observed  when  the  plasma  C – peptide  level  was  increased  to  
2.1 nmol/l (6.34 ng/ml ).  Glomerular  hyperfiltration  was  reduced  by  7 %
34
.  
Whether  the  effect  on  glucose  metabolism  reflects  increased  glucose  
utilisation  or  suppression  of  endogenous  hepatic  glucose  production  is  
unknown,  but  enhanced  peripheral  glucose  utilisation  seems  to  be  one  
possible  explanation,  since  glucose  uptake  increases  in  the  forearm  during  
C- peptide  infusion
35
.  This  suggest  that  C – peptide  is  of  physiological  
importance  for  the  maintenance  of  normal  blood  flow  and  capillary  
function  and  that  C – peptide  may  have  a  role  in  the  regulation  of  
carbohydrate  metabolism. 
C- peptide  is  not  biologically  inert  as  previously  believed.  The  
intracellular  signal  transduction  involves  the  activation  of  calcium  
dependent  signalling  pathways,  with  subsequent  stimulation  of  Na+ - K+  
ATPase  and  Enos  activities
36
.  Both  of  these  systems  show  attenuated  
activities  particularly  in  renal  and  nervous  tissue.  There  is  now  evidence  
to  indicate  that  replacement  of  C – peptide  in  type 1  diabetes  is  
accompanied  by  improved  renal  function,  as  evidenced  by  correction  of  
glomerular  hyperfiltration  and  amelioration  of  nerve  dysfunction
37
.     (19) 
  
KINETICS  AND  THE  VALIDITY  OF  C – PEPTIDE  AS  A  MARKER  
OF  INSULIN  SECRETION  : 
Plasma  C – peptide  concentrations  can  be  used  to  determine  the  insulin  
secretion  rates.  The  validity  of  C- peptide  measurements  as  an  indicator  
of  beta  cell  secretion  depends  on  following  assumptions : 
A)  C – peptide  and  insulin  are  secreted  in  equimolar  quantities ,  the  C- 
peptide : insulin  ratio  approximates  1.0
38
 
B) Hepatic  extraction  of  C – peptide  is  negligible  under  physiologic  
conditions 
39
.  In  humans,  portal  to  peripheral  C – peptide  ratio  is    
1.4  in  the  fasting  state. 
 
The  overall  kinetics  of  C – peptide  is  known  under  the  condition  studied,  
and  the  behaviour  of  C- peptide  in  the  systemic  circulation  is  such  that,  
its  rate  of  appearance  can  be  predicted  from  its  plasma  concentrations
40
.  
The  plasma  C – peptide  has  a  half life  of  approximately  30  minutes. 
URINARY  C- PEPTIDE  AS  A  MEASURE  OF  INSULIN  
SECRETION  
It  has  been  proposed  as  an  indicator  of  endogenous  insulin  secretion,  
because  in  both  lean  and  obese  non – diabetic  subjects  and  in  most  
studies  of  patients  with  NIDDM,                                                                 (20) 
  
urinary  C- peptide  has  been  found  to  correlate  with  plasma  C- peptide  
levels.  Further  more  in  children  with  IDDM  urinary  excretion  may  be  
the  parameter  of  choice  as  it  can  be  measured  by  non – invasive  
procedures 
41
. Several  studies  also  indicate  that  urinary  C – peptide  
estimation  can  be  a  more  sensitive  indicator  of  residual  beta  cell  
function  in  patients  with  IDDM  of  long  duration. 
The  relatively  high  urinary  clearance  of  C- peptide  and  the  absence  of  
significant  hepatic  uptake,  suggest  that  urinary  C- peptide  might  be  a  
reliable  indicator  of  the  amount  of  insulin  secreted  over  specific  time  
intervals.  Small  amount (5 % )  of  secreted  C- peptide  appears  in  the  
urine  and  so  decrease  in  GFR  results  in  decline  in  urinary  C- peptide  
clearance  leads  to  a  large  change  in  the  quantity  of  urinary  C- peptide. 
 
CLNICAL  APPLICATION  OF  C- PEPTIDE  : 
C- peptide  has  been  the  most  important  research  tool  in  the  study  of  
natural  course  of  beta  cell  destruction  and  of  therapeutic  interventions  
to  arrest  or  delay  this  process
42
.  Most  IDDM  patients  have  residual  
beta  cell  function  at  the  onset  of  their  disease  and  all  continue  to  
secrete  insulin  during  the  first  2  years.                            
                                                                                                               (21) 
  
Thereafter  the  prevalence  of  residual  beta  cell  function  declines  to  about  
10 – 15 %  after  approximately  5  years  and  remains  at  this  level  in  
patients  with  upto  40  years  duration. 
The  age  at  onset  of  the  disease  is  the  most  important  variable  in  
predicting  the  duration  and  magnitude  of  residual  beta  cell  function
43
.  
Thus,  the  younger  the  subjects  are,  at  disease  onset,  the  shorter  is  the  
beta  cell  survival.  During  the  first  2  years  after  diagnosis,  a  faster  
reduction  in  residual  beta  cell  function  has  been  demonstrated  in  patients  
having  islet  cell  antibodies  positive  and  in  males
44 
 as  opposed  to  females.  
After  initiation  of  insulin  therapy  and  subsequent  metabolic  stabilisation,  
most  diabetic  subjects  experience  an  improvement  in  beta  cell  function.  
On  average,  beta  cell  function  doubles  in  magnitude  after  7 – 14  days  of  
conventional  insulin  treatment.  In  most  patients,  maximal  beta  cell  
function  is  observed  after  1 – 6  months  of  insulin  treatment.  The  patients  
with  highest  concentration  at  onset  will  display  the  best  degree  of  beta  
cell  function  during  the  first  1- 2  years  after  diagnosis
45
.  The  clinical  
remission  is  a  result  of  both  an  improvement  in  endogenous  insulin  
secretion  and  an  enhancement  in  insulin  sensitivity. 
     On  the  other  hand,  remaining  beta  cell  function  has  been  found  to 
     protect  the  blood  retinal - barrier  function  more  effectively                      (22) 
  
than  good  metabolic  control
46
.  A  significant  inverse  relationship  between  
residual  beta  cell  function  and  the  degree  of  retinopathy  has  been  
observed. 
USE  OF  C- PEPTIDE  IN  CLASSIFICATION   AND  PREDICTION  
OF  INSULIN  REQUIREMENT  : 
It  is  important,  both  for  scientific  and  for  therapeutic  purposes  to  monitor  
the  beta  cell  function  in  diabetic  patients.  The  classification  of  newly  
diagnosed  patients  with  DM  is  normally  without  problems  in  young  
patients  with  ketoacidosis.  There  are  however  patients  with  less  straight  
forward  classification,  usually  middle  aged  or  elderly  patients.  Even  when  
these  patients  present  with  hyperglycaemia  and  ketoacidosis,  some  can  be  
managed  without  insulin  after  treatment  of  the  initial  metabolic  
decompensation
47
.  Other  patients  may  progress  towards  insulin  
dependency,  but  cannot  initially  be  distinguished  from  other  NIDDM  
patients. 
A  group  of  NIDDM  patients  may  need  insulin  to  control  symptomatic                
hyperglycaemia.  In  other  patients  starting  insulin  treatment  during  periods  
of  intercurrent  disease,  insulin  is  often  continued  unnecessarily.  This  
heterogeneity  makes  it  difficult  to  classify  patients  according  to  clinical  
criteria.                                                                                                            (23)  
  
Measurement  of  C- peptide  after  beta  cell  stimulation  appears  to  be  a  
useful  aid  for  decisions  regarding  DM  classification  and  clinical  
management. 
OTHER  USES  OF  C- PEPTIDE : 
a) IN  DIFFERENTIAL  DIAGNOSIS  OF  HYPOGLYCAEMIA : 
Values  will  be  low  if  a  person  has  taken  an  overdose  of  insulin                                                                       
but  not  suppressed  if  hypoglycaemia  is  due  to  an  insulinoma  or       
sulphonylureas. 
 
b) IN  POLYCYSTIC  OVARIAN  SYNDROME  :  To  determine  the  
degree  of  insulin  resistance . 
c) To  monitor  insulin  production  after  the  removal  of  a  tumor  of  the    
pancreas ( insulinoma ) .                         
                 
 
                   GLYCATED   HAEMOGLOBIN  :  HbA1c 
 
Glycated  haemoglobin  comprise  HbA1  and  other  haemoglobin- glucose  
adducts,  whereas  HbA1  is  made  up  of  HbA1a,  HbA1b  and  HbA1c.  
HbA1c  is  the  major  component  of  HbA1,                                                 (24) 
  
accounting  for  80 %.  Glycated  proteins  are  formed  post translationally      
from  the  slow,  non- enzymatic  reaction  between  glucose  and  amino groups  
on  proteins.   
 
 
Table  showing  HbA1c  values  indicating  the  various  stages  of  glycaemia : 
             HbA1c   targets             % 
Normoglycaemia            4 – 6.0 
At  high  risk  of  diabetes            5.7 – 6.4 
Diabetes            6.5 
Diabetes  with  good  glycaemic  
control 
           7.0 
Diabetes  at  higher  risk  of  
hypoglycaemia 
          7.5 
 
Recently  the  ADA,  the  European  Association  for  study  of  Diabetes  and  
the  WHO  have  recommended  the  use  of  HbA1c  levels  ≥ 6.5%  for  
diagnosing  diabetes  mellitus.  Levels  between  5.7 – 6.4 %  indicate  increased  
risk  for  diabetes. 
ADVANTAGES  of  using  HbA1c  : 
 Random  sampling  of  whole  blood.                                                   (25) 
  
 High  biological  stability.                                                                      
 Unaffected  by  acute  factors  such  as  stress,  physical  activity. 
 Index  of  long  term  status  of  glycaemia48 
 Predicts  development  of  vascular  complications  of  diabetes49 
 Helps  to  guide  treatment. 
DISADVANTAGES  : 
Affected  by  various  factors  such  as  factors  influencing  RBC  life  span 
(hemolysis),  erythropoiesis (iron,  vitamin  B12  deficincy),  chronic  liver  or  
renal  problems,  splenectomy. 
GOAL  in  type  2  DM   patients  on  therapy,  aims  to  keep  HbA1c  < 7%   
and  in  patients  having  HbA1c  > 8% , treatment  regimen  should  be  
modified. 
MONITORING  OF  HbA1c  :  Testing  should  be  done  at  least  two  times  
a  year  in  patients  meeting  treatment  goals  and  more  frequently  in  patients  
whose  therapy  has  changed  or  who  are  not  meeting  glycaemic  goals
50
. 
Hence  it  is  best  to  continue  using  HbA1c  as  a  monitor  for  effectiveness  
of  glycaemic  therapy  and  indicator  for  when  therapy  needs  to be  
modified
51
.                                                                     
                                                                                                                    (26) 
  
INSULIN  RESISTANCE : 
Condition  in  which  body‟s  cells  become  resistant  to  the  effects  of  insulin.  
That  is  the  normal  response  to  a  given  amount  of  insulin  is  reduced.  As  
a  result,  high  levels  of  insulin  are  needed  in  order  to  have  its  proper  
effects
52
.  So  the  pancreas  compensates  by  trying  to  produce  more  and  
more  insulin  until  the  pancreas  can  no  longer  produce  sufficient  insulin  
towards  the  body‟s  demands,  then  blood  sugar  rises53. 
 
CONTRIBUTION  OF  INSULIN  RESISTANCE  IN  SKELETAL 
MUSCLE:   
     
In  a  normal  person,  75 %  of  glucose  in  carbohydrate  meal  is  taken  up  
by  the  muscle  and  stored  as  glycogen.  In  insulin  resistant  patients  given  
supraphysiologic  insulin  infusion,  glycogen  synthesis  in  skeletal  muscle  is  
decreased  more  than  oxidative  metabolism.  When  physiologic  insulin  
levels  are  maintained,  both  muscle  glycogen  storage  and  glucose  oxidation  
are  impaired
54.
The  insulin  receptor  levels  and  tyrosine  kinase  activity  in  
skeletal  muscle  are  reduced,  but  these  alterations  are  secondary  to  
hyperinsulinemia  and  are  not  a  primary  defect.   
 
                                                                                                                          (27) 
  
ABNORMAL  INHIBITORS  :     Insulin  resistance  in  NIDDM  may  be  
the  result  of  inhibition  of  insulin  action.  Inhibition  of  insulin  receptor  
(tyrosine  kinase),  by  a  membrane  glycoprotein  called  PC – I55,  was  
increased  in  fibroblasts  of  patients  with  typical  NIDDM. 
 
INSULIN  RESISTANCE  IN  ADIPOCYTES  : 
Insulin  resistance  in  adipose  tissue  may  play  a  role  in  the  obese  diabetic  
patients.  The  cellular  content  of  GLUT 4,  the  facilitative  glucose  
transporter  of  adipocytes  and  skeletal  muscle  is  reduced  by  40 %  in  
obese  patients  without  NIDDM  and  by  85 %  in  obese  patients  with  
NIDDM.  The  increased  fat  cell  mass  of  obesity  in  addition  to  being  
intrinsically  insulin  resistant  may  export  insulin  resistance  to  muscle  both  
by  releasing  FFA  into  general  circulation  and  by  infiltrating  muscle  with  
adipocytes ( marbleization  of  muscle ).  The  concentration  of  glycerol  in  
intrinsic  fibres  of  muscle  are  42  times  higher  than  in  plasma
56
,  making  it  
likely  that  marbleized  muscle  of  obese  individuals  is  exposed  to  high  
levels  of  substrate  released  from  adipocytes  such  as  FFA  and  TNF – 
alpha. 
 
FREE  FATTY  ACIDS  : 
Elevated  plasma  FFA  in  obesity  can  cause  insulin  resistance
57
,  probably  
by  inhibiting  muscle  glucose  metabolism  and                                            (28) 
  
inducing  hyper insulinemia  through  upregulation  of  low  km  glucose  
metabolism  in  islets
58
.  Fat  cells  store  fuel  in  the  form  of  TG‟s  at  times  
of  metabolic  abundance  and  release  FFA  and  glycerol  when  food  is  not  
available.  FFA  release  conserves  the  dwindling  supply  of  glucose,  the  
essential  fuel  for  CNS,  by  substituting  for  glucose  as  fuel  and  thereby  
limiting  glucose  utilisation  in  tissues  for  which  it  is  not  essential (i.e. 
skeletal  muscle )
59
.  Because  glucose  is  spared  in  times of  glucose  need,  
the  increase  in  fatty  acyl  CoA  in  tissues  prolongs  the  survival  time  of  
starving  organism. 
 
TNF  alpha  : 
 It  has  important  effects  on  whole  body  lipid  and  glucose  metabolism.  
TNF alpha  can  cause  many  changes  seen  in  insulin  resistant  state
60
.  It  
downregulates  GLUT 4  mRNA  levels,  inhibits  glucose  transport,  impairs  
the  tyrosine  kinase  activity  of  insulin  receptors,  by  lowering  its  
autophosphorylation  and  decreases  the  phosphorylation  of  IRS – 1  through  
activation  of  phosphotyrosine  phosphatase
61
. 
So,  insulin  resistance  associated  with  obesity  accounted  for  increased  
levels  of  FFA  and  TNF alpha.  However  insulin  resistance  in  lean  glucose  
tolerant  relative  of  NIDDM  patient  cannot  be  explained  on  this  basis  and  
probably  involves  defect  in  skeletal  muscle. 
                                                                                                                          (29) 
  
OBESITY  AND  INSULIN  RESISTANCE   
Obesity  induced  hyperinsulinemia  results  from  both  an  expansion  of   beta  
cell  mass  and  from  an  increase  in  low  Km  gene  metabolism  in  enlarged  
islets.  A  hyperinsulinemic  obese  patient   becomes  overtly  diabetic,  only  if  
the  beta  cells  do  not  maintain  the   hyperinsulinemia  at  a  level  sufficient  
to  counteract  insulin  resistance. 
 
RELATION  BETWEEN  BETA  CELL  DYSFUNCTION  AND  
PERIPHERAL  INSULIN  RESISTANCE  IN  TYPE  2  DM  : 
Islet  dysfunction  and  peripheral  insulin  resistance  coexist  in  overt  NIDDM  
as  noted  previously.  First  possibility  is  that  insulin  resistance  is  the  
primary  lesion  and  causes  a  secondary  defect  in  beta  cell  function  
through  exhaustion
62
.  Second  possibility  is  hyperinsulinemia  could  be  the  
initial  lesion  and  insulin  resistance,  a  secondary  defence  against  
hyperinsulinemia.  A  third  possibility  is  that  both  the  insulin resistance  and  
beta  cell  changes  could  be  secondary  to  a  common  abnormality  such  as  
high  levels  of  FFA. 
The  co- existence  of  high  FFA  and  hyperinsulinemia  is  a  evidence  of  
resistance  in  adipocytes  to  the  antilipolytic  action  of  insulin,  suggesting  
that  a  primary  antilipolytic  insulin  resistance  in  adipocytes  causes  a  
secondary  glucoregulatory  insulin  resistance  in  muscle. 
                                                                                                                          (30) 
  
                              
 
                                         PATHOPHYSIOLOGY 
 
  The  cardinal  manifestation  of  DM  is  hyperglycaemia  and  results  from  : 
1. Inadequate  insulin  secretion  from  β  cells  of  pancreas. 
2. Insulin  resistance  in  peripheral  tissues   
Leads  to  increased  glucose  production   from  liver  and   
decreased  glucose  uptake  in  cells  particularly  muscle  and  adipose tissue. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     (31) 
  
 
Polyuria,  polydipsia  and  weight  loss  occurs.  Insulin  deficiency  leads  to  
high  levels  of  plasma  glucose.  After  a  certain  level  
( > 180 mg/dl )  the  maximum  level  of  renal  tubular  reabsorption  of  
glucose  is  exceeded  and  sugar  is  excreted  in  urine.  The  urine  volume  
is  increased  owing  to  osmotic  diuresis  and  coincident                        (32) 
  
obligatory  water  loss.  This  inturn  leads  to  dehydration,  thirst  and  
excessive  drinking.  Glycosuria  causes  substantial  loss  of  calories (i.e.) 4.1 
K cal/gm  of  glucose  excreted,  thus  resulting  in  weight  loss. 
In  the  absence  of  insulin,  catabolic  activity  of  protein  and  lipids 
predominates.   When  the  liver‟s  ability  to  oxidise  FA  to  carbondioxide  is  
exceeded,  beta hydroxy butyric  acid  and  acetoacetic  acid  accumulate.  Initial  
compensation  occurs  by  increasing  respiratory  loss  of  carbon dioxide,  but  
if  unchecked  leads  to  diabetic  ketoacidosis. 
 
PATHOGENESIS  OF  DIABETIC  COMPLICATIONS  : 
 
The  links  between  hyperglycaemia  induced  oxidative  stress  and  diabetic  
complications
64
  are  as  follows : 
 
 
 
 
 
 
 
 
                                                                                                      (33) 
  
 
                               PATHOGENESIS  OF  DIABETIC  COMPLICATIONS 
ROLE  OF  POLYOL  PATHWAY - DM  and  atherosclerosis : 
Both  are  associated  with  high  incidence  in  females.  MI,  CVA  and  
peripheral  vascular  occlusive  disease  can  occur
65
.                                      (34) 
  
DIABETIC  MICROANGIOPATHY  : 
It  affects  small  vessels,  especially  of  kidneys  and  eyes.  It  affects  
capillaries,  occasionally  arterioles  and  venules
66
.  Thickening  of  capillary  
walls  by  deposition  of  PAS  positive  material  beneath  endothelial  cells.  It  
is  seen  in  all  tissues  except  adipose. 
 
DIABETIC  NEPHROPATHY  :       It  is  the  commonest  manifestation  of  
microangiopathy.  30 – 40 %  of  type 1  and  15 – 20 %  of  type  2  patients  
develop  nephropathy.  Typical  lesion  is  glomerulosclerosis ( diffuse  or  
nodular ).  Nodular  glomerulosclerosis  present  as  Kimmelsteil  Wilson   
lesion 
67
 due  to  hyaline  deposition  in  mesangium. 
 
DIABETIC  RETINOPATHY  :   Due  to  selective  degeneration  of  
pericytes  from  retinal  capillaries
68
. 
 
DIABETIC  NEUROPATHY  :     Peripheral  nerves  are  involved  due  to  
occlusion  of  vasanervosum.  There  is  symmetric  distal  polyneuropathy  due  
to  Schwann  cell  injury  causing  myelin  degeneration. 
 
 
 
                                                                                                                                            (35) 
  
                                           Figure  6 
 
 
The  above  diagram  showing  complications  of  diabetic  mellitus  : 
Neuropathy,  nephropathy,  retinopathy,  stroke,  peripheral  vascular  disease  
and  coronary  artery  disease. 
                                                                                                                                     (36) 
  
                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                         
 
The  above  diagram  depicting  features  of   diabetic  retinopathy ( proliferative 
&  non- proliferative  retinopathy )  like  hemorrhages,  cotton wool  spots  and 
Neovascularisation. 
                                                                                                                     (37) 
 
  
DIAGNOSIS  OF  DIABETES  MELLITUS  : 
Criteria  for  the  diagnosis  : 
1)  Symptoms  of  diabetes  plus  random  blood  sugar  concentration          
≥ 200 mg/dl  or 
2)  Fasting  plasma  glucose       ≥ 126 mg/dl  or 
3)  Two  hour  plasma  glucose  ≥  200 mg/dl  during  an  OGT. 
 IMPAIRED  GLUCOSE  TOLERANCE  : 
       1)  Fasting  plasma  glucose       : 100 – < 126 mg/dl 
        2) Two  hour  plasma  glucose  : 140 – <200  mg/dl  during  an  OGT.           
                                                                
 
                              MANAGEMENT  OF  TYPE  2  DM 
 
The  goals  of  treatment  in  type  2  DM  is  to  control  symptoms, 
achievement  of  fasting  blood  glucose  < 126 mg/dl,  HbA1c  < 7 %  and  
management  of  complications  due  to  long  standing  DM.   The  UKPDS  
demonstrated  that  intensive  blood  glucose  control  using  oral  
hypoglycaemic  agents  and  insulin  can  substantially  decrease  the  risk  of  
the  micro vascular  complications  like  retinopathy,                                      (38)                                                                                                                       
  
neuropathy  and  nephropathy  in  adults  with  type 2  DM.                                                                                                     
However  the  UKPDS  did  not  reveal  any  significant  decrease  in  macro- 
vascular  complications  through  the  control  of  blood  glucose  alone.  
 
GENERAL  PRINCIPLES  : 
DIET  AND  EXERCISE : 
               Lifestyle  modifications  are  important  components  of  the  treatment  
of  type  2  DM.  Weight  loss  improves  insulin  sensitivity  in  obese  non- 
diabetic  subjects
 69
;  This  has  also  been  shown  to  ameliorate  insulin  
resistance,  but  may  not  restore  beta  cell  dysfunction
70
.  UKPDS  study  
showed  that  the  effect  of  diet  therapy  was  transient,  reducing  plasma  
glucose  levels  and  TG‟s,  increasing  HDL  cholesterol71.   
 
PHARMACOLOGICAL  THERAPY  : 
  1.  Insulin, 
  2.  Insulin  secretagogues, 
  3.  Insulin  sensitizers, 
  4.  α - glucosidase  inhibitors72 , 
  5.  Bile  acid  sequestrants  and 
  6.  Newer  drugs :  Amylin  analogue,  GLP-1 analogue,  DPP 4                                                  
inhibitors  and  SGLT-2  inhibitors. 
                                                                                                                          (39) 
  
INSULIN  : 
1.Rapid  acting  -  Lispro,  Aspart  and  glulisine. 
2.Short  acting -  Regular  insulin.  Given  30  minutes  before  a  meal. 
3.Intermediate  acting  -  Isophane  insulin ( NPH ).  They  are  given  twice  a  
day. 
4.Long  acting -  Glargine  and  Detemir ;  They  are  peakless  insulin  and  
provide  a  basal  level  of  insulin  for  24 hours
73
. 
 
INSULIN  SECRETAGOGUES  :\ 
Two  types,  sulfonylureas  and  non- sulfonylureas. 
SULFONYLUREAS  : 
    1
st
  generation  :  Tolbutamide  and  chlorpropamide. 
    2
nd
 generation  :  Glyburide,  glipizide,  glimepiride
74 
,                                       
glycazide  and  glibenclamide. 
Their  principal  mechanism  of  action  is  the  stimulation  of  insulin  secretion  
from  the  pancreatic  beta   cells  in  response  to  glucose
75
.  Hypoglycaemia  is  
the  important  side  effect. 
NON- SULFONYLUREAS   -  Repaglinide  and  nateglinide
76
 
These  agents  are  taken  30  minutes  before  food.  Hypoglycaemia  and  
weight  gain  are  side  effects .                                                                        (40) 
  
INSULIN  SENSITISING  AGENTS  : 
Biguanides  and  thiazolidinediones. 
Biguanides  :    Metformin. 
Acts  by   inhibiting  hepatic  glycogenolysis
77
 ,  thus  decrease  glucose  
production  from  the  liver.  May  be  used  as  monotherapy  at  diagnosis  of  
type  2  DM.  Best  taken  with  meals  to  minimize  GI  upset .   
Thiazolidinediones  :  Rosiglitazone  and  Pioglitazone. 
Acts  by  binding  to  PPAR,  thus  improving  sensitivity  of  liver  &  tissues  
to  insulin
78
.   They  decrease  FFA  and  lower  TG  concentration
79
 .  They  
cause  weight  gain.  Liver  disease  is  under  scrutiny  and  peripheral  edema  
may  occur. 
 
 GLUCOSE  ABSORPTION  INHIBITORS  : 
They  competitively  inhibit  the  alpha  glucosidase  in  the  brush  border  of  
enterocytes  of   the  GIT,  preventing  the  breakdown  of  oligo  and  
disaccharides  into  monosaccharides
80
. 
DRUGS :    Acarbose,  miglitol  and  voglibose. 
Adverse  effects  are  bloating,  abdominal  discomfort,  diarrhoea  and  
flatulence
81
.                                                                                                      (41) 
  
NEWER  DRUGS  : 
 
AMYLIN  ANALOGUES  :  They  are  non- insulin  injectables.     
Pramilintide  is  a  synthetic  analogue  co secreted  with  insulin. 
Mechanism  of  action  : 
1. Gastric  emptying  rate  is  slowed,  thus  reducing  postprandial  rise  in  
blood  sugar. 
2. Reduce  glucagon  levels  post prandially 
3. Inhibits  Ghrelin,  leads  to  early  satiety83 
           Adverse  effects :  Nausea,  vomiting, loss  of  appetite  and            
                                         hypoglycaemia. 
 
 
INCRETIN  MIMETICS  : 
Incretins  are  insulin  secretagogues.  They  are  Glucagon  like  peptide – 
1(GLP-1)  and  gastric  inhibitory  peptide (GIP).  Both  are  rapidly  inactivated  
by  the  enzyme  DPP- 4 
84
. 
                                                   
                                                                                                                          (42) 
  
                                                                                                                                    
                                     Figure  8  -   ACTION  OF  INCRETIN
 
GLP –1   ANALOGUE  :   Bind  to  a  membrane  GLP – 1  receptor. As  a  
result,  it  inhibits  glucagon  secretion  and  stimulates  insulin  release  from  
pancreatic  beta  cells. These  analogues  are  not  degraded  by  DPP- 4. 
Analogues  are  Exenatide,  Liraglutide  and  Taspoglutide. 
DPP – 4  INHIBITORS  :   Increase  blood  concentration  of  the  incretin, 
GLP- 1  by  inhibiting  its  degradation  by  the                                               (43) 
  
enzyme  DPP- 4. 
Drugs  used  are :      sitagliptin,  saxagliptin,  vildagliptin,  linagliptin. 
BILE  ACID  SEQUESTRANTS  :   Colesevelam 
Used  as  an  add  on  therapy  for  type  2  DM. 
Initially  approved  to  lower  LDL  cholesterol;  then  approved  for  use  in  
type 2  DM  in  2008. 
Dose  :  1875  mg  orally  twice  a  day  with  meals. 
 
SGLT- 2 ( Sodium  glucose  transporters – 2 )  inhibitors  : 
Block  the  re-uptake  of  glucose  in  the  renal  tubules,  promoting  loss  of  
glucose  in  the  urine. This  causes  both  mild  weight  loss  and  a  mild  
reduction  in  blood  sugar  levels  with  little  risk  of  hypoglycaemia. 
                Side  effect :  Urinary  tract  infection. 
                DRUGS  :     Canagliflozin   and   Dapagliflozin. 
 
 
                                                                                                                          (44)  
  
 
  
 
          METHODOLOGY                                      
                                                                          
 
 
 
 
 
                               
  
SELECTION  OF  CASES  : 
50  type  2  DM  patients  who  attended  the  diabetic  outpatient  clinic  of  our  
hospital   were  randomly  selected  for  the  study, then  methods,  procedures  
of  the  study  were  adequately  explained  to  the  patient  and  consent  
obtained.  The  study  subjects  were  asked  to  come  in  the  fasting  state,  
after  cessation  of  taking  oral  medications  for  type  2  DM  for  3  days.  
Then  sample  for  FBS  &  C- peptide  were  taken  in  the  fasting  state  and  
its  level  estimated. 
 
INCLUSION  CRITERIA  : 
      Type 2  diabetes  mellitus  patients. 
 
EXCLUSION  CRITERIA : 
A.  Type 1  diabetes  mellitus  patients. 
B.   Patients  with  acute  infections, renal failure  and  pregnancy. 
 
 
 
                                                                                 (45) 
  
ESTIMATION  OF  C –PEPTIDE  
    For  estimation  of  C- peptide  two  methods  are  available : 
1)  ELISA ( Enzyme  linked  immuno  sorbent  assay ) 
2)  CLIA ( Chemi luminescent  immunoassay ) -  For  serum  C- peptide  
level  estimation  in  quantities.   
 
PROCEDURE  OF  CLIA : 
It  is  based  on  a  solid  phase  ELISA. In  this  test,  microtiter  well  coated 
with  anti C – peptide  antibody  and  horseradish  peroxidase  enzyme  labelled  
with  anti-C-Peptide  antibody  is  used. To the  anti-C-Peptide antibody coated  
microtiter wells,  the standards  and  test specimen  are added. Then  the  
enzyme  labelled  anti-C-Peptide  antibody  is added  to  the  well. If  C- peptide  
is  present  in  the  serum  then  it  forms  a  sandwich  between the solid phase 
and enzyme-linked antibodies. Then  chemi luminescent  substrate is  added and 
read  in a Luminometers.  
Amount of  C-peptide  present  in the sample  is  estimated  by  the  intensity  of  
emitting  light  measured  by  Luminometers. 
 
 
                                                                                                                    (46) 
  
MATERIALS  REQUIRED  : 
Anti-C-Peptide Antibody Coated Microtiter Wells - 96 wells 
Enzyme conjugate reagent  - 12 ml 
Reference Standard :  0, 0.5, 1.0, 2.0, 5.0, and 10.0 ng/ml, liquid, ready for use 
                                       - 1 set 
50x Wash Buffer -  15 ml 
Chemiluminescence Reagent A -  6.0 ml 
Chemiluminescence Reagent B  - 6.0 ml 
 
PRECAUTIONS  : 
All  products  that  contain  human  serum  have  been  found  to be  non-
reactive for Hepatitis B Surface  antigen,  HIV 1&2  and  HCV antibodies . 
   
 
LIMITATIONS : 
1. Heterophile  antibodies   in  human  serum,  interfere  with  in vitro  
immunoassays. 
2. Lipemeic,  hemolysed  samples  should not be used. 
 
 
                                                                                                             (47) 
  
 
MEASUREMENT  OF  BMI  : 
Also  called  Quetelet  index,  is  defined  as  the  body  mass   divided  by  
the  square  of  the  body  height  and  is  expressed  in  units  of  kg/m
2  
 
                                          
           BMI  =        Weight  in  kilogram      
                            Height  in  metre  square            
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           1.   DISTRIBUTION  OF  THE  PATIENTS  BASED  ON  AGE 
                                                      TABLE - 1 
         
 
 
 
 
 
 
 
 
 
 
 
              
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  with  type  2  
DM,  a  maximum  of   19 (38 %)  cases  were  between  the  50 – 59 years,  13 
(26 %)  cases  were  between  the  40-49  years. 
        Mean  age  group  =  54.40  ±  10.319.                                                  
                                                                                                                          (49) 
 Age  groups 
 NO. OF  CASES 
(n=50) 
 
100% 
30 to 39yrs 2 4.0 
40 to 49yrs 13 26.0 
50 to 59yrs 19 38.0 
60 to 69yrs 12 24.0 
70yrs & 
above 
4 8.0 
    
             50 
 
            100 
  
                                            
                                                     AGE WISE  DISTRIBUTION  
                                                     Figure  1  
 
                                                                         AGE  GROUPS 
                                                                 
                                                                                                                                      (50) 
0
5
10
15
20
25
30
35
40
30 to 39yrs 40 to 49yrs 50 to 59yrs 60 to 69yrs 70yrs & above
%
 o
f 
P
a
ti
e
n
ts
Series1
  
                   2.       DISTRIBUTION  OF  THE  PATIENTS  BASED  ON  SEX 
                                                              TABLE  - 2 
 
  SEX 
No. of cases 
(n=50) 
  
100% 
MALE 27 54.0 
FEMALE 23 46.0 
 
 
    
            50 
 
 
         100 
 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  DM,     
males  constitute  27 (54 %)  and  females  constitute   23 (46 % ). 
 Male  :  Female  =  1.17  :  1                                                
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                       DISTRIBUTION  OF   THE  PATIENTS  BASED  ON  SEX 
                                                   Figure -  2 
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3. DISTRIBUTION  OF  THE  PATIENTS  BASED  ON   DM  
DURATION  : 
                                                   TABLE  3 
 
 
     DURATION 
No. of cases 
(n=50) 
 
100% 
       <  5  Years 30 60.0 
        ≥  5  Years 20 40.0 
 
 
 
                  50 
 
 
        100 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  DM,   
30 (60 %)  patients  had  DM  with  duration  of   <  5 years  and  the  remaining  
20 (40 %)  had  DM  with  duration  of  ≥ 5 years. 
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DISTRIBUTION  OF  THE  PATIENTS  BASED  ON   DM    DURATION  
 
                                                       Figure - 3 
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4. DISTRIBUTION    OF  THE  PATIENTS  BASED  ON  THE   
PRESENCE     OR  ABSENCE  OF  FAMILY  HISTORY   :                                                                      
                                               TABLE  4 
 
 
 
 
FAMILY  H/O 
NO.  OF  CASES 
(n=50) 
 
100% 
Yes 23 46.0 
No 27 54.0 
 
 
 From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  
DM,    23 (46 %)  patients  has  family  history  of  DM  and  the  remaining  27 
(54 %)  had  no  family  history. 
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 DISTRIBUTION    OF  THE  PATIENTS  BASED  ON   PRESENCE   OR   
ABSENCE  OF  FAMILY  HISTORY   : 
                                                         Figure  4 
 
 
              
 
                                                                                                                         (56) 
Yes, 46 % 
No, 54 % 
Yes No
  
    5.  DISTRIBUTION  OF  THE  PATIENTS  ON  THE  BASIS  OF  BMI 
 
                                                   TABLE  5 
 
           BMI 
NO. OF 
CASES 
(n=50) 
 
100% 
Obese ( ≥ 25) 23 46.0 
Non-obese (< 25 ) 27 54.0 
 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  DM, 
23 ( 46 % )  patients  had  BMI  ≥ 25  and  the  remaining  27 ( 54 % )  patients    
had  BMI  < 25 .  
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                                              DISTRIBUTION  BASED  ON  BMI  
                                                      Figure  5 
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6. DISTRIBUTION  OF  THE  PATIENTS  ON  THE  BASIS  OF                           
FASTING  C- PEPTIDE  LEVELS  
 
                                                         TABLE  6 
 
 C-PEPTIDE   
   LEVELS 
NO.  OF  CASES 
(n=50) 
 
100% 
<  0.6 ng/ml 6 12.0 
0.6 to 1ng/ml 12 24.0 
1 to 2 ng/ml 17 34.0 
2 to 3 ng/ml 11 22.0 
≥ 3ng/ml  4 8.0 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  DM,   
fasting  C- peptide  levels  of  < 0.6 ng/ml  was  found  in  6 (12 %)  patients ,   
0.6 – 1 ng/ml   was  found  in  12 (24 %)  patients,  1-2   ng/ml  in  17 (34 %)  
patients  and  > 2 ng/ml  in   15 ( 30 %)  of  patients.   
                                                                                                                         (59) 
  
DISTRIBUTION  OF  THE  PATIENTS  ON  THE  BASIS  OF                           
FASTING  C- PEPTIDE  LEVELS                                          
                                             Figure   6 
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            7.    FASTING  BLOOD  SUGAR  LEVELS  IN  TYPE  2  DM 
 
                                                      TABLE  7 
 
          FBS 
No.of Patients 
(n=50) 
Percentage 
(100%) 
< 150 mg% 23 46.0 
150 to 200 
mg% 
14 28.0 
200 to 250 
mg% 
10 20.0 
 > 250  mg% 3 6.0 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  cases  of  type  2  DM,  
23 (46%)  patients  had  FBS  level  below  150  mg/dl,  14 (28%)  patients  had  
FBS  level  between  150 – 200 mg/dl,  13  (26%)  patients  had  FBS  level   
above  200 mg/dl. 
                          Mean  FBS  =  166.32  ±  44.215. 
                                                                                                                                                                      (61) 
 
  
                                      DISTRIBUTION  BASED  ON  FBS  LEVELS 
                                                                                Figure  7 
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                                         DESCRIPTIVE  STATISTICS 
 
 
                     Parameters Min Max Mean S.D 
1.  Age(yrs) 36 83 54.40 10.319 
2.  Duration of Diabetes in Years 1 240 67.02 66.478 
3.  Height  ( cms ) 139 171 156.82 8.337 
4.  Weight  (kg) 38 81 59.24 9.642 
5.  BMI 16 35 24.15 3.907 
6.  Fasting C-peptide (ng/ml) 0.37 4.93 1.5900 0.99284 
7.  Fasting blood sugar  (mg/dl) 86 260 166.32 44.215 
 
 
 
                                                                                                (63) 
 
  
8. C- PEPTIDE  LEVEL  AND  BMI  CORRELATION  IN  TYPE 2  DM 
                                              TABLE  8 
FASTING C-PEPTIDE 
(ng/ml) 
BMI 
Statistical 
inference 
Obese 
(n=23) 
Non-obese 
(n=27) 
Total 
(n=50) 
               <   0.6      ng/ml 2 (8.7%) 4 (14.8%) 6 (12%) 
X 
2
= 24.405. 
 
P = 0.010 <  0.05 
Significant. 
       0.6 to 1       ng/ml 4 (17.4%) 8 (29.6%) 12 (24%) 
        1 to 2       ng/ml 8 (34.8%) 9 (33.3%) 17 (34%) 
        2 to 3      ng/ml 7 (30.4%) 4 (14.8%) 11 (22%) 
           ≥ 3       ng/ml  2 (8.7%) 2 (7.4%) 4 (8%) 
 
 
From  the  above  table  it  was  inferred  that  out  of  50  patients,  23 (46%)  
patients  were  obese,  among  the  obese  patients  : 17  patients  had  adequate  
or  higher  C- peptide  levels  and  low  C- peptide  level  of  < 0.6 ng/ml  was  
found  only  in  2 (8.7%)  patients. 
Non- obese  patients  constitute  27 (54%)  of  the  50  cases.  Among  them,  8 
(29.6%)  patients  had  C- peptide  level  in  the  range  of  0.6-1 ng/ml,  9 
(33.3%)  patients  had  1-2 ng/ml,  6 (22.1%)  patients  had  > 2 ng/ml  and  4 
(14.8%)  patients  had  < 0.6 ng/ml. 
In  this  study,  it  was  found  that  there  is   positive  correlation  between  
BMI  &  C- peptide  levels  as  indicated  by  P  value                                    (64) 
  
which  is  significant  (P= 0.010) . So,  the  C- peptide  level  increases  with  
increase  in  BMI  indicating  the  resistance  to  insulin  action.         
               FASTING  C-PEPTIDE   AND  BMI  CORRELATION 
                                               Figure  8 
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                    9.  ASSOCIATION  OF  BMI  AND  FBS  LEVEL 
                                                TABLE  - 9 
                                            Chi- square  test 
FASTING BLOOD 
SUGAR  
( mg%) 
BMI 
Statistical 
inference 
Obese 
(n=23) 
Non-obese 
(n=27) 
Total 
(n=50) 
       <  150   mg% 7 (30.4%) 16 (59.3%) 23 (46%) 
X
2 
= 20.248  
P = 0.036  <  0.05 
 Significant 
 
150 to 200   mg% 8 (34.8%) 6 (22.2%) 14 (28%) 
200 to 250   mg% 6 (26.1%) 4 (14.8%) 10 (20%) 
         ≥  250  mg%  2 (8.7%) 1 (3.7%) 3 (6%) 
 
From  the  above  mentioned  table  it  was  inferred  that  out  of  50  patients, in  
the  obese  group  of  23(46%)  patients ,   FBS  level  was  ≥ 150 mg/dl  in  16 
(69.6%)  patients, <150  mg/dl  in  only  7 (30.4%)  patients. 
In  the  non- obese  group  of  27  patients,  16 (59.3%)  patients  had  FBS  level  
below  150 mg/dl  and  11 (40.7%)  patients  had  level  above  150 mg/dl. 
The  above  observation  suggests  that  the  association  between  FBS  levels  
and  BMI  was  significant (p= 0.036)  and  positively  correlated,  indicating  
that  in  obese  patients  inspite  of  elevated  C-peptide  levels,  FBS  levels  
increased  due  to  insulin  resistance.                                                     
                                                                                                                         (66)                                   
  
             Figure  9    :   ASSOCIATION  OF  BMI  AND  FBS  LEVELS 
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    10.  ASSOCIATION  OF  FASTING  C- PEPTIDE  AND  FBS  LEVEL     
                                                   TABLE  10 
                                                 Chi- square  test 
FASTING 
C-PEPTIDE 
(ng/ml) 
FASTING BLOOD SUGAR (mg%) 
Statistical 
inference 
Below 150        
mg% 
(n=23) 
150 to 200 
mg% 
(n=14) 
200 to 
250mg% 
(n=10) 
250 
mg% & 
above 
(n=3) 
Total 
(n=50) 
<  0.6  0 2(14.3%) 3 (30%) 1 (33.3%) 6 (12%) 
X
2 
= 16.119 
Df=12 
P = 0.186 
 (> 0.05) 
Not 
Significant 
0.6 to 1 5 (21.7%) 4 (28.6%) 2 (20%) 1 (33.3%) 12(24%) 
1 to 2  11(47.8%) 3 (21.4%) 3 (30%) 0 17(34%) 
2 to 3  5 (21.7%) 5 (35.7%) 1 (10%) 0 11(22%) 
≥ 3 2 (8.7%) 0 1 (10%) 1 (33.3%) 4(8%) 
 
From  the  above  mentioned  table  it  was  inferred  that  out  of  50  patients,  
those  with  C-peptide  level  < 0.6 ng/ml, fasting  plasma  glucose  level  
between  150-200 mg/dl  was  found  in  2  patients  & fasting  plasma  glucose  
level  above  200 mg/dl  was  found  in  4  patients   .  
Among  29  patients  with  C-peptide  level  between  0.6 - 2 ng/ml,  fasting  
plasma  glucose  level  between  150-200 mg/dl  was                                     
                                                                                                                          (68) 
  
 
found  in 7  patients , above  250 mg/dl  was  found  in  6  patients    and  16  
patients  had  level  below  150 mg/dl. 
Among  15  patients  with   C-peptide  level  > 2 ng/ml, FBS  < 150 mg/dl  was  
found  in  7  patients  and   > 150 mg/dl  was  found  in  8  patients.  
From  the  above  mentioned  data  it  was  inferred  that , the  fasting  C-peptide  
and  fasting  blood  sugar  level  associations  were  not  significant  as  
indicated  by  the  P  value (P = 0.186). 
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   10.  ASSOCIATION  OF  FASTING  C- PEPTIDE  AND  FBS  LEVELS 
                                                   Figure  10 
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             11. ASSOCIATION  OF  DURATION  OF  DIABETES  AND  BMI 
                                                      TABLE  11 
                                                    Chi- square  test 
DURATION  
OF 
DIABETES  
BMI 
Statistical 
inference 
Obese 
(n=23) 
Non-obese 
(n=27) 
Total 
(n=50) 
<  5 years 15 (65.2%) 15 (55.6%) 30 (60%) 
X 
2
= 0.483; 
    Df =1 
    P = 0.487  
      (>0.05) 
Not Significant 
≥  5 years 8 (34.8%) 12 (44.4%) 20 (40%) 
 
 
 
The  above  table  shows  that  in  this  study,  among  23  obese  patients,  
duration  of  diabetes  was  < 5  years  in  15  patients  and  ≥ 5  years  in  8  
patients.  Among  27  non- obese  patients,  duration  of  diabetes  was  < 5  
years  in  15  patients  and  ≥ 5  years  in  12 patients.  The  association  between  
BMI  and  duration  of  diabetes  were  not  significant  (P = 0.487). 
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                 12.  ASSOCIATION  OF  DURATION  OF  DIABETES  AND   
                                     FASTING  C- PEPTIDE   LEVELS  
                                                      TABLE  12 a 
  
FASTING C-
PEPTIDE (ng/ml) 
DURATION OF DIABETES 
Statistical 
inference <  5  YEARS 
(n=30) 
≥ 5 YEARS 
(n=20) 
Total 
(n=50) 
<  0.6  1 (3.3%) 5 (25%) 6 (12%) 
X
2
=12.593 Df=4 
 
P = 0.013 
(<0.05) 
 
     Significant 
0.6 to 1 6 (20%) 6 (30%) 12 (24%) 
1 to 2  9 (30%) 8 (40%) 17 (34%) 
2 to 3  10 (33.3%) 1 (5%) 11 (22%) 
> 3 4 (13.3%) 0 4 (8%) 
 
             
From  the  above  mentioned  table  it  was  inferred  that  out  of  50  patients,  
DM  duration  < 5  years  was  found  in  30  patients,  among  which  C- 
peptide  level  of  1-2 ng/ml  was  found  in  9  patients,  > 2 ng/ml  in  14  
patients  and  < 0.6 ng/ml  in  1  patient. 
DM  duration  ≥ 5  years  was  found  in  20  patients,  among  which  C- 
peptide  level  of  < 0.6 ng/ml  was  found  in  5  patients,  0.6-1 ng/ml  in  6  
patients  and  > 2 ng/ml  in  1  patient.                                                            
                                                                                                                          (73) 
  
From  the  above  observed  data  it  was  inferred  that  there  was  negative  
correlation   between  DM  duration  and   C- peptide  level  in  this  study,  as  
indicated  by  significant  P  value (P = 0.013). So,  the  C-peptide  level  
decreases  with  increase  in   DM  duration. 
     
 DM  DURATION  AND  MEAN  C- PEPTIDE  LEVEL  CORRELATION 
                                                  TABLE  12 b 
    
   DM  duration 
 
   NO.  of  cases 
    C- peptide 
   Mean  ±  SD 
Test  applied 
  ( T – test ) 
      <  5  years            30 1.953 ± 1.031      T = 3.518 
      ≥  5  years            20 1.045 ± 0.629 P = 0.001(< 0.05) 
    Significant 
 
 
From  the  above  table  it  was  inferred  that ,  by  comparing  the  mean ± SD  
of  C- peptide  with  patients  of   DM  duration  < 5  years  and   ≥ 5  years  by  
T- test ,  it  was  found  that  the  association  were  significant  as  denoted  by  
T  value  (3.518)  and  P  value (P = 0.001),  thus  the  C- peptide  level  
decreases  with   increase  in  DM  duration                                                    (74) 
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               ASSOCIATION  OF  DURATION  OF  DM  AND   FBS  LEVEL 
                                                  TABLE   13 
FASTING BLOOD 
SUGAR (mg%) 
DURATION OF DIABETES 
Statistical 
inference <  5  YEARS 
(n=30) 
≥ 5  YEARS 
(n=20) 
Total 
(n=50) 
< 150  19 (63.3%) 4 (20%) 23 (46%) 
X
2
=10.121 Df=3 
 
P = 0.018 (<0.05) 
Significant 
150 to 200 7 (23.3%) 7 (35%) 14 (28%) 
200 to 250 3 (10%) 7 (35%) 10 (20%) 
≥ 250 1 (3.3%) 2 (10%) 3 (6%) 
 
The  above  table  shows  that,  among  30  patients  with  duration  of  DM  < 5  
years,  19  patients  had  FBS  level  < 150 mg/dl  and  only  4  patients  had  
FBS  level  above  200 mg/dl.  Among  20  patients  with  duration  of  DM  ≥ 5  
years, 9  patients  had  FBS  level  > 200 mg/dl  and  only  4  patients  had  FBS  
level  < 150 mg/dl.   
This  observation  suggests  that  there  is  an  association  between  duration  of  
DM  and  FBS  levels  as  indicated  by  P  value  which  was  found  to  be  
significant (P = 0.018).  This  association  had  moderately  positive  correlation,  
as  indicated   by  increase  in  fasting  plasma  glucose  values  with  increase  
in  DM  duration.                                                                                             (76) 
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COMPARISON  OF  AGE  WITH  MEAN  FASTING  C-PEPTIDE  
LEVEL  IN  PATIENTS  WITH  BMI  <  25 (Non- obese). 
                                                   TABLE   14 a 
   
Particular 
No.of patients 
(n=27) 
Percentage 
(100%) 
Non-obese 27 100.0 
                                                     
                                                 Oneway  ANOVA ( Non- obese) 
FASTING C-PEPTIDE 
(ng/ml) 
Mean S.D SS DF MS 
Statistical 
inference 
Between Groups   0.691 3 0.230 
F=78 
P = 0.841 (>0.05) 
Not Significant 
 
40 to 49yrs (n=5) 1.3780 0.71054    
50 to 59yrs (n=10) 1.3970 1.09673    
60 to 69yrs (n=9) 1.5989 0.82442    
70yrs & above (n=3) 1.0600 0.62746    
Within Groups   19.070 23 0.829 
 
 
The  above  table  shows  that  there  is  no  association  between  fasting  C-
peptide  level  and  age ,  in  patients  with  BMI  <  25,  as  the  P  value  is  not  
significant  (P = 0.841).                                                                                     
                                                                                                                          (78) 
  
COMPARISON  OF  AGE  WITH  MEAN  FASTING  C-PEPTIDE  
LEVEL  IN  PATIENTS  WITH  BMI  ≥  25 (obese). 
                                                   TABLE   14 b 
Particular 
No.of Patients 
(n=23) 
Percentage 
(100%) 
Obese 23 100.0 
 
                                           Oneway  ANOVA (Obese ) 
FASTING C-
PEPTIDE (ng/ml) 
Mean S.D SS DF MS 
Statistical 
inference 
Between Groups   12.505 4 3.126 
F=3.907 
P = 0.219  
(> 0.05) 
Not  
Significant 
30 to 39yrs (n=2) 0.9200 0.19799    
40 to 49yrs (n=8) 1.4438 0.70737    
50 to 59yrs (n=9) 2.4233 1.15302    
60 to 69yrs (n=3) 0.7600 0.33719    
70yrs & above (n=1) 3.5900 0.000    
Within Groups   14.405 18 0.800 
 
The  above  table  shows  that  there  is  no  association  between  fasting  C-
peptide  level  and  age ,  in  patients  with  BMI  ≥  25, as  the  P  value  is  not  
significant (P = 0.219).                                                                                     (79) 
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                                             DISCUSSION 
In  this  study,  there  are  totally  50  patients  labelled  as  type  2  DM,  of  
which  female  patients  constitute  23 (46%)  and  males  constitute  27 (54%). 
Age group  of  study  patients  is  in  the  range  of  30-80  years.  The  age  
group  in  the  range  of  50-60  years,  constitute  maximum  number  of  study  
patients .  Mean  age  was  found  to  be  54.40 ± 10.319. 
Khatib  et  al
   
 in
86  
 his  study  also  showed   that  the  50- 60  years  age  group  
constitute  many  type  2  DM  cases. 
In  this  study,  60 %  patients  had  DM  duration  of  <  5  years,  while  40 %  
had  duration  of  ≥ 5 years. 
As  per  ADA  2002  recommendation,  patients  with  BMI  ≥ 25  is  considered  
obese.  In  this  study,  23 (46%)  patients  were  considered  obese  and  
27(54%)  patients  were  considered  non- obese  as  measured  by  BMI. So,  it  
is  inferred  from  the  study  that  obesity  plays  an  important  role  in  the  
development  of  insulin  resistance  and  subsequent  type  2  DM. 
INSULIN  SECRETORY  FUNCTION  : 
By  measuring  C-peptide  levels  in  the  fasting  state,  insulin  secretion  from  
the  β  cell  of  pancreas  was  measured  in  this  study. Because  C- peptide  is  
secreted  from  β  cell  of  pancreas  along  with  insulin  in  equal  amounts  and  
it  undergoes  only  negligible  liver  extraction                                               (80) 
  
and  its  level  in  the  peripheral  blood  equals  to  that  of  in  the  portal  blood,  
C- peptide  is  used  as  a  measure  of  insulin  secretion  in  the  body. 
In  this  study,  C- peptide  level  was  found  to  be  adequate  or  high  in  44  
patients ( indicating  good  insulin  reserve )  and   low  in  6  patients  
( indicating  poor  insulin  reserve). 
 Mean  C-peptide  level  in  this  study  was  1.590 ± 0.992. 
 
OBESITY  AND  C- PEPTIDE  LEVEL : 
In  this  study,  obese  patients  had  mean  C- peptide  level  of  1.82 ng/ml  
while  non- obese  patients  had  1.30 ng/ml,  indicating  that  obese  patients  
had  higher  mean  C- peptide  levels  compared  to  non- obese  group,  this  
association  shows  positive  correlation  as  measured  by  P  value  which  is  
significant ( x
2  
= 24.405,  P = 0.010 ). In obese  patients  resistance  to  insulin  
action  occurs  resulting  in  elevated  insulin  levels  as  evidenced  by  
increased  C- peptide  levels.   
Study  conducted  by  Snehalatha,  A.  Ramachandran   et  al
88    
also  showed  
that  the  insulin  secretion  was  lesser  in  non- obese  compared  to  obese  
individuals.  Andrea  Tura  et  al 
89 
 in  his  study  measured  insulin  and  C-
peptide  levels  during  a  3  hour  oral  glucose  tolerance
    
tests.              (81) 
  
S.W. Park  et  al
 90  
in  his  study  noticed  that  there  is  an  association  
between  BMI  and  serum   C-peptide  levels  which  were  positively  
correlated.  
  
.  
Banerjee  et  al  in  his  study  showed  that   Asian  Indians  have  high   body  
fat  relative  to  muscle  mass  and  BMI;  they  have  increased  resistance  to  
insulin  action  at  cellular  level  resulting  in  elevated  serum  insulin  levels. 
 
 
ASSOCIATION  OF  FASTING  PLASMA  GLUCOSE  AND   
C- PEPTIDE  LEVELS  : 
         
In  this  study,  association  between  fasting  C-peptide  level  and  FBS  levels  
were  not  significant  as  the  P  value  is  0.186. 
Clare,  Jones  O  et  al 
92 
in  their  study  noticed  that  the  obese  patients  had  
elevated  serum  insulin,  C- peptide  and  blood  glucose  levels  than   non-
obese  patients. 
Relimpio  F  et  al 
93
  studied    C-peptide/ blood  sugar  level  association  in  
type 2 DM  patients  treated  with  oral  hypoglycaemic  drugs. 
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ASSOCIATION  OF   BMI  AND  FBS   LEVELS: 
In  this  study  it  is  noticed  that  there  is  an  association  between  BMI  &  
fasting  plasma  glucose  levels. They  were  positively  correlated  as  indicated  
by  the  P  value  which  was  found  to  be  significant (P = 0.036). 
So,  it  is  inferred  that  FBS  level  increases  with  increase  in  BMI, 
indicating  the  increased  resistance  to  insulin  action  in  obese  individuals. 
 
ASSOCIATION  OF  INSULIN  SECRETION  AND  DM  DURATION : 
In  this  study ,  patients  with  DM  duration  <  5  years  had  mean  C- peptide  
level  of  1.953 ± 1.031,  while  patients  with  duration  of  diabetes  ≥ 5  years  
had  mean  C- peptide  level  of  1.045 ± 0.629.   
 Negative  correlation  was  found  between  insulin  secretion  and  duration  of  
DM  as  indicated  by  significant  T  value (  3.518)  &  P  value (0.001),  
indicating  that  insulin  secretion  from  β  cell  of  the  pancreas  decreases  
with  increase  in  DM  duration. 
 
ASSOCIATION  OF  BMI  AND  DURATION  OF  DM : 
 In  this  study  it  was  found  that  the  association  between  BMI  and  DM  
duration  was  not  significant  as  measured  by  P  value .  
                                                                                                       (83) 
  
                                                                                                                  
DURATION  OF  DM  and   FBS  level  : 
The  previous  table  shows  that,  among  30  patients  with  duration  of  DM  < 
5  years,  19  patients  had  FBS  level  < 150 mg/dl  and  only  4  patients  had  
FBS  level  above  200 mg/dl.  Among  20  patients  with  duration  of  DM  ≥ 5  
years, 9  patients  had  FBS  level  > 200 mg/dl  and  only  4  patients  had  FBS  
level  < 150 mg/dl.   
This  observation  suggests  that  there  is  association  between  duration  of  
DM  and  FBS  levels  as  P  value  is  significant (P = 0.018).  The  association  
was  found  to  be  moderately  positively  correlated,  indicating  that  as  the  
duration  of  diabetes  increases,  FBS  levels  increases. 
 
 
FAMILY  HISTORY  :   
In  this  study,  it  was  found  that  46 %  patients  had  family  history  of  DM ,  
while  the  remaining  54 %  had  no  family  history  of  DM. 
Study  conducted  by  Shobha  Malini  et  al 
95
 noticed  58 %  patients  had  
family  history  of  DM.                                       
                                                                                                                           
  (84)    
 
  
 
                     LIMITATIONS  OF  THIS  STUDY  : 
1. The  sample  size  of  patients  with  type 2  diabetes  mellitus  taken  
for  this  study  were  small. 
2.  Obese  patients  with  type  2  diabetes  mellitus  constitute  less  than  
50 %  of  the  total  sample  studied. 
3. Glycosylated  haemoglobin   level  estimation  for  the  study  
subjects  were  not  done  in  this  study. 
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                   CONCLUSION 
 
 
 
 
 
 
                                 
 
  
CONCLUSION : 
1. Nearly  88 %  patients  had  adequate  insulin  reserve  of  > 0.6 ng/ml.  The  
obese  patients  had  higher  C- peptide  levels  compared  to  the  non- obese  
patients  indicating  insulin  resistance. 
2. The  insulin  reserve  decreased  with  the  increase  in  duration  of  diabetes  
as  seen  by  the  decrease  in  fasting  C-peptide  levels. This  indicates  that  
the  β  cell  dysfunction  increases  with  the  duration of  diabetes. 
3. Minority  of  the  patients  had  very  low  C- peptide  levels  and   require  
insulin  therapy.  The  obese  patients  with  adequate  insulin  reserve,  
require  dietary  and  exercise  management  along  with  oral  
hypoglycaemic  drugs  to  improve  the  level  of  insulin  sensitivity  to  
receptors. 
In  Conclusion,  this  study  suggests  : 
*   Early  screening  of  subjects  with   family  history  of  diabetes,   
     *   C-peptide  testing  should  be  done  in  patients  with  poor  blood             
           glucose  control  to  decide  treatment  modalities    and 
      *  To  create  awareness  about  lifestyle  modifications  and  education  to   
           prevent  obesity. 
 
                                                                                                                          (86) 
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NAME : 
AGE  :                      SEX :                         HOSPITAL NO : 
 
SYMPTOMS  : 
 
POLYURIA  VOMITING & DIARRHOEA  
POLYDYPSIA  NUMBNESS  & 
PARESTHESIA 
 
LOSS  OF  WT.  PRURITIS  
POLYPHAGIA  DIMNESS  OF  VISION  
TIREDNESS  OTHERS  
WT.  GAIN    
 
PAST  HISTORY  : Hypertension,  ischemic  heart  disease,  Chronic   
                                  Kidney  disease,  others. 
DRUG  HISTORY  : 
 
PERSONAL  HISTORY  :  Smoking,  alcohol,  tobacco / betel  nut. 
                                                                                                              
          FAMILY  HISTORY  :    Diabetes  mellitus -   Yes / No                  (100) 
  
 
EXAMINATION  : 
HEIGHT : 
WEIGHT : 
BODY  MASS  INDEX  : 
 
GENERAL  EXAMINATION  : 
 
        Anemia,  clubbing,  pedal edema,  ingrowing  toe  nail,  ulcer, 
        Dermopathy,  icterus,  Jugular  venous  pulse. 
          VITALS  : 
    PULSE  RATE  : 
    BLOOD  PRESSURE : 
 
SYSTEMIC  EXAMINATION  : 
 
CARDIOVASCULAR  SYSTEM  : 
 
RESPIRATORY  SYSTEM  : 
          ABDOMINAL  SYSTEM  :                                                               (101)    
  
          CENTRAL  NERVOUS  SYSTEM  : 
 
EYE  :     Cataract  : 
                Fundus  : 
 
FOOT  EXAMINATION  : 
 
INVESTIGATIONS  : 
1. Complete  blood  count  : 
2. Serum  Urea  : 
3. Serum  Creatinine  : 
4. ECG  : 
5. Chest  X- ray  PA  view : 
6. Fasting  blood  sugar  : 
7. Fasting  C- peptide  : 
8. URINE  -     Albumin   
                     Sugar 
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OF 
DIABETES 
FAMIL
Y 
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(Cm) 
 
WEIG
HT 
(Kg) 
 
BMI 
 
 
FASTING C- 
PEPTIDE 
(ng/ml) 
 
FASTING 
BLOOD 
SUGAR(mg%) 
 
1. 
 
 
ABDUL 
MUTHULEAF 
 
71 
 
 
M 
 
 
2   YRS 
 
 
 YES 
 
 
165 
 
 
55 
 
 
20.2 
 
 
        0.77 
 
 
       140 
 
2. 
 
AROCKIA 
SAMY 
 
50 
 
M 
 
2   Months 
 
 NO 
 
152 
 
63 
 
27.3 
 
        1.35 
 
       139 
3. BALAGURU 40 M 6  YRS NO 163 70 26.3         0.52        160 
4. BARATHI 50 F 3  YRS NO 151 53 23.2         3.22        124 
5. BANUMATHI 55 F 6  YRS NO 154 63 26.6         0.93        260 
6. BASKAR 40 M 3  YRS YES 167 60 21.5         1.00        110 
7. GUNASEKARA
N 
50 M 2  YRS NO 168 65 23         0.88        139 
8. JAHEER  USEN 40 M 7  YRS YES 165 75 27.5         1.80        172 
9. JEYALAXMI 62 F 8  YRS YES 150 57 25.3         0.84        130 
10. JEYARAMAN 48 M 3  YRS YES 170 65 22.5        1.88       148 
11. JOSEPH 63 M 5  YRS NO 167 60 21.5         2.42       140 
12. KALYANI 54 F 1   Month YES 139 51 26.4         2.87       180 
13. KARUNANIDHI 44 M 5   Months NO 168 72 25.5         0.70       124 
14. MANGALAM 65 F 1    YR NO 150 51 22.7         2.13       114 
15. MANI 60 M 15  YRS YES 159 60 23.7         2.81       167 
16. MANICKAM 62 M 15  YRS NO 166 59 21.4         0.62       236 
17. NAGARAJAN 55 M 11  YRS NO 163 55 20.7         1.29       180 
18. NARAYANAN 60 M 20  YRS YES 158 65 25.4         0.39       210 
19. NOORJAHAN 55 F 6   Months NO 150 79 35.1         2.94       168 
20. PADMAVATHI 38 F 2   Months YES 148 55 25.1         1.06       110 
21. PANDIAMMAL 52 F 5   YRS YES 153 67 28.6         2.01       141 
22. PONMANI 60 F 13  YRS YES 153 51 21.8         0.71       155 
23. POUNAMBAL 40 F 3   Months NO 158 57 22.8         2.15       128 
24. PREMA 52 F 5   Months YES 159 54 21.4         3.47       130 
25. RAJA 58 M 3   YRS YES 148 55 25.1         1.86       140 
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 RANI 
 
40 
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9   YRS 
 
 
 NO 
 
 
146 
 
 
57 
 
 
26.7 
 
 
        1.21 
 
 
       210 
 
27. 
 
SAMIPILLAI 
 
77 
 
M 
 
13  YRS 
 
 NO 
 
163 
 
60 
 
22.6 
 
        0.63 
 
       168 
28. SAROJA 40 F 2  YRS YES 149 53 23.9         1.49        112 
29. SARAVANAN 6O M 4  YRS NO 168 60 22        1 .40        120 
30. SEKAR 55 M 2  YRS YES 160 65 25.4         2.38        196 
31. SELVAM 45 M 1  YR NO 164 70 26         2.55        120 
32. SELVARAJ 44 M 4  YRS YES 159 40 16         0.37        208 
33. SHANTHI 48 F 3  YRS YES 153 75 32         1.47        178 
34. SUBRAMANY 80 M 20  YRS NO 155 50 20.8         1.78        146 
35. SUSAI MARY 57 F 9  YRS NO 153 38 16.2        0.42       198 
36. SUSEELA 59 F 14  YRS NO 144 47 22.7         1.35       141 
37. THAMBAIAH 69 M 2   YRS YES 171 64 21.9         1.87       132 
38. THANGARAJ 64 M 8  YRS NO 156 43 17.7         0.56       210 
39. THANGARASU 65 M 15    YRS YES 151 53 23.2         1.87       108 
40. THIAGARAJAN 52 M 2  YRS YES 164 70 26         2.54       200 
41. VASANTHA 
PRIYA 
49 F 6  YRS YES 140 50 25.5         1.10       221 
42. VASANTHA 55 F 1  YR NO 153 66 28.2         4.93       256 
43. VEERALAXMI 48 F 2  YRS NO 146 57 26.7         2.20       210 
44. VEERAYAN 71 M 2  YRS NO 159 68 26.9         3.59       204 
45. VELLAISAMY 56 M 7  YRS YES 164 58 21.6         0.62       241 
46. VIJAYA 50 F 6  Months NO 146 52 24.4         0.80       158 
47. VIJAYALAXMI 36 F 1  MONTH YES 156 81 33.3         0.78       180 
48. VIOLET MARY 60 F 15   YRS NO 148 64 29.2         1.05       212 
49. VISWANATHA
N 
55 M 8   Months NO 171 64 21.9         1.52       86 
50. YUVARANI 58 F 7  YRS NO 158 40 16         0.40       256 
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